Reweighed Charlson comorbidity index more accurate in men with prostate cancer

Article

A reweighed Charlson comorbidity index (CCI) based on prostate cancer-specific data and long-term follow-up predicts long-term, other-cause mortality in prostate cancer patients better than the original CCI.

Key Points

Washington-A reweighed Charlson comorbidity index (CCI) based on prostate cancer-specific data and long-term follow-up predicts long-term, other-cause mortality in prostate cancer patients better than the original CCI, according to UCLA researchers.

Based on its performance, the revised CCI may be useful for counseling men about management of early-stage prostate cancer, said first author Timothy Daskivich, MD, a urology resident at UCLA's David Geffen School of Medicine working with Mark S. Litwin, MD, MPH, and colleagues.

Related Videos
Sad surgeon sitting on floor in corridor | Image Credit: © WavebreakMediaMicro - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Man talking with doctor | © DragonImages - stock.adobe.com
Kevin Turner MA DM FRCS(Urol), answers a question during a Zoom video interview
A panel of 3 experts on overactive bladder
A panel of 3 experts on overactive bladder
human kidney stones medical concept | Image Credit: © freshidea - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.